Figure 2.

Cumulative survival. (A): Overall survival (OS) of Ewing sarcoma patients receiving vincristine, ifosfamide, and doxorubicin (VID) for initial therapy stratified by the extent of disease (localized n = 42 vs. metastatic n = 29) at initial presentation. (B): Event‐free survival of patients presenting with a localized disease. (C): OS of patients presenting with localized disease stratified by percent necrosis after initial treatment with VID (≥95% necrosis n = 21 vs. <95% necrosis n = 13). (D): OS of patients presenting with a localized disease stratified by the site of primary (pelvic n = 9 vs. other n = 33).

Abbreviation: Cum, cumulative.